AngioDynamics’ DIRECT clinical study features a comprehensive data collection strategy that will provide meaningful clinical information to healthcare professionals, support a regulatory indication ...

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F18 85 System in pulmonary embolism treatment.

COLONIE — Latham's AngioDynamics is alleging that a major competitor in the medical device market, C.R. Bard, is violating anti-trust laws in the sale of its catheters. In a lawsuit filed in U.S.

For the period, which ended Nov. 30, AngioDynamics' sales grew by less than 3% year over year to $79.1 million, missing Wall Street's consensus estimate of $82 million. The company also suffered a ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

AngioDynamics saw a stronger-than-expected rebound with FQ4 revenue, and boosted guidance for FY'22, while also providing an encouraging three-year outlook for meaningful growth acceleration.

Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter ...

Trowbridge announced, "Based on our first quarter performance and our expectations for the balance of the year, we now expect net sales to be in the range of $308 million to $313 million, raised from ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...

AngioDynamics, Inc. ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance ...

AngioDynamics Inc (NASDAQ: ANGO) has reported a Q4 FY23 adjusted EPS of $0.02, in line with the consensus EPS higher than $0.01 a year ago. Q4 sales increased 4.7% Y/Y to $91.07 million, beating the ...

AngioDynamics reported mixed fiscal 2025 Q1 results. The medical technology company has had some good news recently, though. AngioDynamics continues to expect modest growth for the full year.